Pretreated EGFRdel19/BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report
oleh: Corrado Orciuolo, MD, Federico Cappuzzo, MD, Lorenza Landi, MD, Blerina Resuli, MD, Silvia Carpano, MD, Antonello Vidiri, MD, Simonetta Buglioni, MS, Chiara Mandoj, MD, Gennaro Ciliberto, MD, Gabriele Minuti, MD
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-08-01 |
Deskripsi
Oncogene-addicted NSCLC inevitably becomes resistant to targeted therapy by developing acquired resistance through on- or off-target mechanisms, potentially detectable by liquid biopsy. We present the first reported case of a patient with pretreated EGFRdel19/BRAFV600E lung adenocarcinoma and symptomatic leptomeningeal metastasis obtaining durable clinical benefit on osimertinib, dabrafenib, and trametinib treatment.